Lilly is announcing a major investment of $3 billion to expand its recently acquired manufacturing facility in Wisconsin. The expansion will significantly boost the production of medicines, including those for diabetes and obesity, benefiting millions of patients worldwide.
The company plans to start construction on the expansion next year, which marks another step in Lilly’s historic manufacturing expansion agenda. Since 2020, Lilly has committed over $10 billion to expanding its manufacturing capabilities.
Lilly aims to accelerate medicine production using advanced automation technologies, including guided vehicles, robotics, and production equipment. The company will also embed digital automation throughout the site to improve processes and accuracy, allowing employees to focus on producing safe and high-quality medicines.
The expansion project is expected to create over 2,000 construction jobs, in addition to new highly skilled positions for operators, technicians, engineers, and scientists.
Lilly plans to advance innovation in pharmaceutical manufacturing by partnering with local higher education institutions and supporting community initiatives. The company aims to harness the power of biotechnology, chemistry, and genetic medicine to tackle some of the world’s most significant health challenges.
As a leading medicine company, Lilly has been pioneering life-changing discoveries for nearly 150 years, and its medicines now help tens of millions of people across the globe. With this expansion, Lilly is committed to making life better for millions more people by delivering innovative clinical trials and ensuring accessible and affordable medicines.
Source: https://investor.lilly.com/news-releases/news-release-details/lilly-announces-3-billion-expansion-its-recently-acquired